Literature DB >> 26376205

Effects of lipopolysaccharide on the expression of plasma membrane monoamine transporter (PMAT) at the blood-brain barrier and its implications to the transport of neurotoxins.

Kuo-Chen Wu1, Ya-Hsuan Lu1, Yi-Hsuan Peng1, Lih-Ching Hsu1, Chun-Jung Lin1.   

Abstract

Plasma membrane monoamine transporter (PMAT) is a polyspecific organic cation transporter that is highly expressed in the central nervous system. This study aimed to investigate the effect of lipopolysaccharide on PMAT expression at the blood-brain barrier and the interaction between PMAT and neurotoxins. As a result, PMAT mRNA was identified in brain microvessels (BMVs), brain microvascular endothelial cells (BMECs), astrocytes, and pericytes isolated from C57BL/6 mice and/or Wistar rats using RT-qPCR. The immunofluorescence staining confirmed the expression of PMAT protein in BMVs and striatum of C57BL/6 mice. Western blotting demonstrated its localization at the luminal and abluminal sides of BMECs. In C57BL/6 mice, PMAT protein was significantly increased in BMVs 24 h after an intraperitoneal injection of 3 mg/kg lipopolysaccharide. Lipopolysaccharide treatment also significantly increased PMAT expression in cerebral cortex and the striatum in a time-dependent manner, as well as the brain-to-plasma ratio of 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-benzyl-TIQ). In isolated cells, lipopolysaccharide treatment significantly increased PMAT mRNA in brain astrocytes and the BMECs co-cultured with astrocytes. In addition to 1-methyl-4-phenylpyridinium, the kinetic study indicated that both 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-benzyl-TIQ are substrates of human PMAT. These findings suggest that inflammation can change PMAT expression at the blood-brain barrier, which may affect PMAT-mediated transport of neurotoxins. We demonstrated the expression of plasma membrane monoamine transporter (PMAT; mRNA or protein) at several subunits of the blood-brain barrier. Lipopolysaccharide treatment can significantly increase the expression of PMAT in vivo (in brain microvessels, cerebral cortex, and the striatum of C57BL/6 mice) and in vitro (in brain astrocytes and brain microvascular endothelial cells co-cultured with astrocytes). Lipopolysaccharide treatment also increased the brain-to-plasma ratio of 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-benzyl-TIQ) in mice, where 1-benzyl-TIQ competitively inhibited 1-methyl-4-phenylpyridinium (MPP(+)) uptake in MDCK-human PMAT (hPMAT) cells and its uptake in MDCK-hPMAT is concentration dependent.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  Blood-brain barrier; PMAT; lipopolysaccharide; neurotoxin

Mesh:

Substances:

Year:  2015        PMID: 26376205     DOI: 10.1111/jnc.13363

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Authors:  T Lee Gilman; Christina M George; Melissa Vitela; Myrna Herrera-Rosales; Mohamed S Basiouny; Wouter Koek; Lynette C Daws
Journal:  Eur J Neurosci       Date:  2018-05-24       Impact factor: 3.386

Review 2.  The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.

Authors:  J Wang
Journal:  Clin Pharmacol Ther       Date:  2016-09-19       Impact factor: 6.875

3.  Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier.

Authors:  Shin-Ichi Akanuma; Myeongrae Han; Yuka Murayama; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2022-02-02       Impact factor: 4.200

4.  Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB).

Authors:  Gayathri N Sekhar; Ana R Georgian; Lisa Sanderson; Gema Vizcay-Barrena; Rachel C Brown; Paula Muresan; Roland A Fleck; Sarah A Thomas
Journal:  PLoS One       Date:  2017-03-31       Impact factor: 3.240

5.  Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease.

Authors:  Gayathri Nair Sekhar; Alice L Fleckney; Sevda Tomova Boyanova; Huzefa Rupawala; Rachel Lo; Hao Wang; Doaa B Farag; Khondaker Miraz Rahman; Martin Broadstock; Suzanne Reeves; Sarah Ann Thomas
Journal:  Fluids Barriers CNS       Date:  2019-12-17

6.  Organic Cation Transporters in Psychiatric Disorders.

Authors:  Lynette C Daws
Journal:  Handb Exp Pharmacol       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.